News | Stents Carotid | December 13, 2022

InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists

Series to feature leading experts discussing the current and future trends in the carotid treatment market

Series to feature leading experts discussing the current and future trends in the carotid treatment market

December 13, 2022 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced a video series, “12 Days of Carotid Stenting,” which will feature leading multidisciplinary vascular specialists discussing the current and future trends in the carotid treatment market. The series will be available for viewing beginning on Monday, November 28, 2022. 

Marvin Slosman, chief executive officer of InspireMD, stated, “This truly unique video series featuring some of the most renowned thought leaders in the field of vascular interventions, and we are grateful that they have taken the time to participate in this important initiative. Topics that will be discussed include current market trends, momentum toward endovascular standard of care, technology differentiation and clinical results, delivery system topics including TCAR and TFEM approaches, and the overall progression of the landscape toward further conversion of surgical interventions to stenting. Importantly, the series will also highlight the distinct advantages of CGuard™ versus competing stent platforms for carotid revascularization and stroke prevention thus supporting our belief that CGuard can soon become the global standard of care for the treatment of carotid artery disease.” 

The video series will feature perspectives from the following thought leaders in the field of vascular interventions: 

  • Chris Metzger, MD, System Chair of Clinical Research at Ballard Health and a practicing interventional cardiologist who serves as Director of Holston Valley Medical Center’s diagnostic catheterization and interventional labs 
  • Sean Lyden, MD, Professor and Chairman of the Department of Vascular Surgery at Cleveland Clinic 
  • Tommaso Castrucci, MD, Vascular, Endovascular and Emergency Vascular Surgery Unit, "S. Eugenio" Hospital, Rome, Italy 
  • Adnan Siddiqui, MD, PhD, FACS, FAHA, FAANS, Director, Canon Stroke & Vascular Research Center at SUNY University at Buffalo, Professor of Neurosurgery & Radiology at University at Buffalo Neurosurgery (UBNS) 
  • Kenneth Rosenfield, MD, Section Head, Vascular Medicine and Intervention at Massachusetts General Hospital and Chairman, ST-Elevation Myocardial Infarction (STEMI) & Acute Myocardial Infarction Quality Improvement Committee 

The full Fireside Chat can be viewed at: www.inspiremd.com/en/fireside-chat-series/, along with brief sections on the company’s LinkedIn page. 


Related Content

News | Heart Failure

May 22, 2024 — New research from The Cooper Institute and partners at University of Texas (UT) Southwestern Medical ...

Home May 22, 2024
Home
News | Heart Failure

April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College ...

Home April 30, 2024
Home
News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
Subscribe Now